Amgen has launched an online portal to support healthcare professionals in Spain whose work involves bowel cancer.
The website, www.canalcolon.com, is focused on metastatic colorectal cancer (mCRC) and content is aimed at all specialists involved in the diagnosis, treatment and monitoring of patients with mCRC.
It is intended to improve clinical practice and to educate healthcare professionals about the potential for personalised medicines in the area.
The portal gives oncologists in Spain access to a range of information, from results of clinical studies to news and events related to mCRC. In sections such as ‘Ask the Expert’, opinion leaders answer questions about the condition.
Users can also access or register with the platform www.ras-amgen.com, which can help them to detect RAS mutations.
Part of the reason for the portal is the continuing rise of personalised medicines for specific types of cancer that are related to gene mutations.
Of particular concern for Amgen in this area is its drug Vectibix (panitumumab), which is approved to treat mCRC patents whose tumour cells contain non mutated (wild-type) ‘RAS’.